The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.
Nancy Samir ElbarbaryEman Abdel Rahman IsmailManal H El-HamamsyMarwa Z IbrahimAmal A El KholyPublished in: Diabetologia (2024)
ClinicalTrials.gov NCT06115460.